ClinicalTrials.gg
TerminatedNCT06568692Updated Oct 6, 2026

A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

A Phase 2 interventional study of PCS6422 and capecitabine and Capecitabine in Breast Cancer, TNBC - Triple-Negative Breast Cancer and HER2-negative Breast Cancer, sponsored by Processa Pharmaceuticals. Terminated at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Primary conditionTriple Negative Breast NeoplasmsRegistry: Breast NeoplasmsReclassifiedWhy we changed it
Registry
Breast Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Triple Negative Breast Neoplasms
Why
  1. The study's listed conditions name Triple Negative Breast Neoplasms, a narrower term within Breast Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Processa Pharmaceuticals · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
Business Reason
Updated Oct 6, 2026Now TerminatedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies testing capecitabine in Triple Negative Breast Neoplasms — 8 open to participants now, 11 under way, 3 of them phase 3. Capecitabine · Triple Negative Breast Neoplasms.

Enrollment
17th of 19
20 · median 154
Started
2024
with 1 other
Phase 2
13 of 19
6 open now
Registered
15th of 19
by date
Lead sponsor
1 of 19
Processa Pharmaceuticals

Among the 19 studies testing capecitabine in Triple Negative Breast Neoplasms, this one is the 17th largest by enrollment, is one of 2 that started in 2024, is one of 13 in phase 2, and was the 15th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

8 of the 19 studies testing capecitabine in Triple Negative Breast Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About capecitabine

Capecitabine: first FDA approval 1998 (XELODA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 329 Triple Negative Breast Neoplasms studies recruiting now, 229 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing capecitabine in Triple Negative Breast Neoplasms, or all of them as a file.
02

Study summary

This is an adaptive Phase 2, open-label, randomized, multi-center study evaluating up to 2 regimens of PCS6422 with capecitabine (Cap) vs. standard dose of Cap alone in patients with advanced or metastatic breast cancer. The goal of the study is to assess the efficacy and safety of PCS6422 + Cap as a treatment option for patients with advanced or metastatic breast cancer who are not eligible for anthracycline- or taxane-containing therapies, or other available therapies, including PD-1 or PARP inhibitors.

Read the detailed description

This is an adaptive Phase 2, open-label, randomized, multi-center study evaluating up to 2 regimens of PCS6422 with Cap vs. standard dose of Cap alone in patients with advanced or metastatic breast cancer who are not eligible for anthracycline- or taxane-containing therapies, or other available therapies, including PD-1 or PARP inhibitors. The goal of the study is to assess the efficacy and safety of PCS6422 + Cap as a treatment option for patients with advanced or metastatic breast cancer who have been treated with chemotherapy in the metastatic setting.

03

Conditions studied

  • Breast Cancer
  • TNBC - Triple-Negative Breast Cancer
  • HER2-negative Breast Cancer

Browse trials for

Keywords

  • HR positive
  • Advanced Breast Cancer
  • Metastatic Breast Cancer
04

In context

Triple Negative Breast Neoplasms Reclassified

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.

This study's enrollment of 20 is below the median of 60 across 1,053 interventional studies indexed under Triple Negative Breast Neoplasms.

Browse Triple Negative Breast Neoplasms studies →

Lead sponsor

Processa Pharmaceuticals is the lead sponsor of 10 studies on the registry; none are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 3 (50%) have results posted.

Compared within Triple Negative Breast Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Breast Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged ≥18 years at Screening
  2. Diagnosis of confirmed breast cancer that is unresectable. The following subsets of breast cancer are included:

    1. Patients with triple-negative breast cancer, advanced or
    2. Patients with hormone receptor (HR) positive, ER positive, negative advanced or metastatic breast cancer
  3. Has in accordance with 1.1 obtained by imaging within 28 days prior to C1D1
  4. Other therapies are not indicated (eg, resistant or intolerant to taxanes and/or an anthracycline-containing regimen) for treatment of advanced or metastatic breast cancer
  5. Has a life expectance of at least 24 weeks
  6. Has Performance Status (ECOG PS) 0 or 1 at screening
  7. Has adequate bone marrow, liver, and renal function as assessed by the following laboratory requirements conducted within 7 days before C1D1 (Note: labs will also be repeated pre-dose on C1D1 to confirm eligibility): a. ≥9 g/dL (≥90 g/L) b. Adequate renal function by estimated (eGFR) defined as a >50 mL/min (>0.84 mL/s) (Cockcroft-Gault equation) and normalized to body surface area c. Peripheral (ANC) of ≥1.5×109/L d. count of ≥100×109/L without growth factor/transfusion e. Total \<1.5× (ULN); or ≤3×ULN if the patient has Gilbert's disease f. (AST) or alanine aminotransferase (ALT) \<2.5×ULN, with liver metastasis \<5×ULN g. (INR) \<1.5 and prothrombin time (PT) ≤1.5×ULN, unless both of the following conditions are met: i. Patient is receiving anticoagulant therapy, and ii. PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulant h. Activated partial thromboplastin time (aPTT) ≤1.5×ULN, unless both of the following conditions are met: i. Patient is receiving anticoagulant therapy, and ii. PT or PTT is within therapeutic range of intended use of anticoagulants

Exclusion criteria

Exclusion Criteria:

  1. Received any for advanced or breast cancer within 21 days or 5 half-lives (whichever is longer) prior to randomization
  2. Currently receiving any hormone replacement therapy, unless discontinued within 21 days prior to randomization
  3. Received IV 5-FU or oral 5-FU analog in the 4 weeks prior to C1D1
  4. Received DPD inhibitor within 4 weeks prior to C1D1
  5. Has homozygous or compound heterozygous DPYD variants that result in complete or near-complete absence of DPD activity
  6. Cardiac:

    1. Has history or presence of abnormal 12-lead (ECG) results, in the Medical Monitor or Investigator's opinion
    2. Has prolonged (with Fridericia's correction) of >480 msec performed at Screening
    3. Has a history of prolonged QTc interval, ventricular tachycardia/fibrillation or significant ventricular arrhythmia, or Torsades de Pointes, or a history of ventricular ablation for arrhythmia
    4. Has congenital long QT syndrome or a family history of long QT syndrome
    5. Has other clinically significant cardiac disease including, but not limited to, myocardial infarction, unstable angina, cardiac or other vascular stenting, angioplasty, or surgery ≤12 months prior to randomization, congestive heart failure

      • Class II per the , or history of myocarditis
  7. Is pregnant or breastfeeding
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    PCS6422 40 mg + Capecitabine 300 mg

    Fixed single dose of PCS6422 administered with Capecitabine 150 mg BID over 7 days

    Drug: PCS6422 and capecitabine

  • Experimental
    PCS6422 40 mg + Capecitabine 450 mg or 150 mg

    Fixed single dose of PCS6422 administered with Capecitabine 225 mg or 75 mg BID over 7 days

    Drug: PCS6422 and capecitabine

  • Active comparator
    Capecitabine 2000 mg/m2

    Standard capecitabine dose at 1000 mg/m2 BID

    Drug: Capecitabine

Interventions

  • DrugPCS6422 and capecitabine

    Drug pages: EniluracilStudies of EniluracilEniluracil pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · CapecitabineStudies of CapecitabineCapecitabine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    PCS6422 is an experimental drug that, when combined with capecitabine, may make the immune response more active against cancer.

    Also known as: eniluracil

  • Commercially available capecitabine is a commonly used oral fluoropyrimidine.

    Also known as: xeloda

07

What researchers measure

Primary outcomes

  1. Evaluation of Objective Response Rate (ORR)

    The proportion of patients who achieved a confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)

    Time frame: Up to 24 weeks post End of Treatment (EoT)

  2. Number of patients with adverse events (AEs)

    Frequency, duration, and severity of AEs across treatment groups

    Time frame: During treatment, an average of 8 months

Secondary outcomes

  1. Evaluation of Disease Control Rate (DCR)

    The proportion of patients with objective evidence of CR or PR or stable disease (SD) according to RECIST 1.1

    Time frame: Up to 24 weeks post End of Treatment (EoT)

  2. Evaluation of Duration of Response (DOR)

    The proportion of patients with DOR

    Time frame: Up to 24 weeks post End of Treatment (EoT)

  3. Evaluation of Time to Response (TTR)

    The number of patients with days to response

    Time frame: Every 12 weeks during treatment

  4. Evaluation of Progression Free Survival (PFS)

    Patients with number of days of progression free response

    Time frame: Up to 24 weeks post End of Treatment (EoT)

08

Study locations

12 sites
  • Valkyrie Clinical Trials
    Los Angeles, California 90067, United States
  • FOMAT Medical Research
    Oxnard, California 93030, United States
  • AP Medical Research
    Miami, Florida 33165, United States
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • Northwest Cancer Center
    Dyer, Indiana 46311, United States
  • University of Maryland Medical Center (UMMC)
    Baltimore, Maryland 21201, United States
  • Rutgers Cancer Institute of New Jersey
    New Brunswick, New Jersey 08901, United States
  • Clinical Research Alliance
    Westbury, New York 11590, United States
  • Gabrail Cancer Center Research
    Canton, Ohio 44718, United States
  • SCRI Oncology Partners
    Nashville, Tennessee 37203, United States
  • Texas Oncology PA (Austin)
    Austin, Texas 78731, United States
  • Texas Oncology PA (San Antonio)
    San Antonio, Texas 78240, United States
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Oct 2024 to primary completion in Jul 2026, 21 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 6, 2026: primary completion Sep 2026 → Jul 2026 and completion Oct 2026 → Jul 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2024
First posted
Aug 23, 2024
StartActual
Oct 2, 2024
Primary completionActual
Jul 29, 2026was Sep 2026
CompletionActual
Jul 29, 2026was Oct 2026
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated Business Reason
changed Oct 6, 2026
Sites
1 site removed
Show 1 removed
  • Arizona Oncology Associates · Tucson, United States
Oct 6, 2026
Primary completion
Sep 2026→Jul 29, 2026 (actual)
Oct 6, 2026
Study completion
Oct 2026→Jul 29, 2026 (actual)
Oct 6, 2026
Enrollment
90 (estimated)→20 (actual)
Oct 6, 2026
Secondary outcomes
3 description edited
What changed in the outcomes
  • DescriptionEvaluation of Duration of Response (DOR): how it is measured was reworded
  • DescriptionEvaluation of Progression Free Survival (PFS): how it is measured was reworded
  • DescriptionEvaluation of Time to Response (TTR): how it is measured was reworded
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Recruiting→Terminated
    Why stopped Business Reason
    1 site removed
    Show 1 removed
    • Arizona Oncology Associates · Tucson, United States
    Primary completion Sep 2026→Jul 29, 2026 (now actual)
    Study completion Oct 2026→Jul 29, 2026 (now actual)
    Enrollment 90 (estimated)→20 (actual)
    Secondary outcomes 3 description edited
    What changed in the outcomes
    • DescriptionEvaluation of Duration of Response (DOR): how it is measured was reworded
    • DescriptionEvaluation of Progression Free Survival (PFS): how it is measured was reworded
    • DescriptionEvaluation of Time to Response (TTR): how it is measured was reworded
    + 5 other changes: verification date, oversight details, arm descriptions, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06568692
Lead sponsor
Processa Pharmaceuticals
Responsible party
Sponsor
First posted
Aug 23, 2024
Start date
Oct 2, 2024
Primary completion
Jul 29, 2026
Completion
Jul 29, 2026
Last update
Oct 6, 2026

Study contacts

Mridula George, MD
principal investigator · Rutgers University

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Eniluracil · Capecitabine

Start the discussion